Sanofi ADS (SNY) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-02, Sanofi ADS (NASDAQ: SNY) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $44.34 (+2.81% 1D, market cap $105.19B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, SNY ranks #178 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SNY carries a Roarable C- (59/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, GSK (GSK plc American) holds a D+ grade (57/100 RQD, P/E 32.8x, ROIC 9.9%, cap $98.47B) and BMY (Bristol-Myers Squibb Company) posts a C grade (63/100 RQD, P/E 17.8x, ROIC 13.3%, cap $125.40B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).
For Sanofi ADS (SNY), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #178 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC Form 4 / 13F Thermometer: 60% Net Buy • Cannibal Buyback (-1.24% YoY Shares)
Macro rate sensitivity & RSI-14 (58.8) create a -11 pt regime headwind
Even with a 59/100 (C-) score, SNY faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($42.10) or 200D SMA ($44.29) invalidates the momentum regime and cuts Target Base ($44.54) toward Bear Floor ($34.74).
Sanofi ADS (SNY) surged +2.81% to $44.34, trading at 39% of its 52-week range ($39.07 – $52.68). Solid steady margins (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
https://www.dars.gov.et/ report covering Sanofi ADS (SNY) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Sanofi ADS (SNY) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Sanofi ADS (SNY) market action, institutional positioning, and fundamental catalysts.
Sanofi walked into its Q3 2026 report with the share price at €79.74 after a solid run over the past month, and the mood already leaning optimistic. The headline was clear: quarterly revenue landed at €15.2b and basic ea
An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters.
Regeneron rallied to a two-year high as Dupixent drives strong Q3 earnings. But is there any further upside left in REGN shares? Let’s find out!
Shares of biotech company Regeneron (NASDAQ:REGN) jumped 11.5% in the afternoon session after the company reported a 36% increase in third-quarter 2026 revenue to $5.1 billion, alongside a 70% rise in non-GAAP diluted ea
Eurozone growth just cooled to 0.4% in Q3, yet still beat forecasts, and that mix of resilience and slowdown is quietly reshaping where money could flow next. Some businesses may benefit if investors rethink how far the
Regeneron stock jumped to a two-year high Friday after its Sanofi-partnered inflammation giant, Dupixent, handily beat expectations.
Moby summary of Regeneron Pharmaceuticals, Inc.'s Q3 2026 earnings call
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -1.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SNY today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SNY. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Sanofi ADS (SNY) ranks #178 by composite RQD confidence (59/100, grade C-) and #22 by equity capitalization ($105.19B). Within this direct 5-issuer industry benchmark cohort, BMY leads on earnings valuation at 17.8x trailing P/E, while VRTX leads on capital efficiency and profitability with 20.0% ROIC and 86.2% gross margin. REGN currently holds the highest overall quantitative score in the immediate peer group at 80/100 (B+) compared with SNY at 59/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SNY
ACTIVE
Sanofi ADS | C- | 59/100 | 32.8x | — | 9.9% | +2.81% | $105.19B | Benchmark Subject |
| GSK GSK plc American | D+ | 57/100 | 32.8x | — | 9.9% | +1.71% | $98.47B | /gsk-vs-sny → |
| BMY Bristol-Myers Squibb Company | C | 63/100 | 17.8x | 71.1% | 13.3% | +1.78% | $125.40B | /bmy-vs-sny → |
| REGN Regeneron Pharmaceuticals Inc. | B+ | 80/100 | 18.7x | — | 9.4% | +13.33% | $84.30B | /regn-vs-sny → |
| VRTX Vertex Pharmaceuticals Incorporated | B+ | 80/100 | 34.6x | 86.2% | 20.0% | +3.50% | $136.87B | /vrtx-vs-sny → |
Sanofi ADS (SNY) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $105.19B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 7/9.
As of 2026-11-02, Sanofi ADS (NASDAQ: SNY) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $44.34 (+2.81% 1D, market cap $105.19B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, SNY ranks #178 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SNY carries a Roarable C- (59/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, GSK (GSK plc American) holds a D+ grade (57/100 RQD, P/E 32.8x, ROIC 9.9%, cap $98.47B) and BMY (Bristol-Myers Squibb Company) posts a C grade (63/100 RQD, P/E 17.8x, ROIC 13.3%, cap $125.40B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).
For Sanofi ADS (SNY), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #178 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
SNY last traded at $44.34 (+2.81% on volume of 15,101,933 shares), positioning the stock +5.32% above its 50-day simple moving average ($42.10) and +0.11% above its 200-day simple moving average ($44.29). Across its 52-week range of $39.07 to $52.68, SNY sits at the 38.7% percentile with a 14-day RSI of 58.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±3.8% ($42.66 to $46.02).
Why SNY Stock surged +2.81% Today — RQD Quant Desk Flash. Solid steady margins (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
Per the Roarable RQD rating, SNY scores 59 out of 100, which corresponds to a letter grade of C- and a verdict label of "Roarable Hold — Cautious Neutral." The five pillars are:
Taken together, the investor implication is that balance-sheet strength provides a floor on downside risk, while valuation (P/E TTM 32.8, EV/EBITDA 21) and a weak macro-fit score temper upside. Upside drivers would be earnings growth that compresses the multiple; valuation tradeoffs center on paying a premium for current earnings with a modest FCF yield. This is an analytical framework, not personalized advice.
Sanofi ADS (SNY) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, it carries a market capitalization of $105.2B. Not available in source data: product lines, customer segments, and revenue model detail.
Risk watch: the guidance-downgrade alert is the most material item to monitor. Proprietary signals: none. Butterfly graph shows no supply-chain links.
Real-time company headlines, analyst actions, and sector developments for Sanofi ADS (SNY) • Click "Debate This Headline" to argue it in the Roar Pit below
https://www.dars.gov.et/ report covering Sanofi ADS (SNY) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Sanofi ADS (SNY) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Sanofi ADS (SNY) market action, institutional positioning, and fundamental catalysts.
Sanofi walked into its Q3 2026 report with the share price at €79.74 after a solid run over the past month, and the mood already leaning optimistic. The headline was clear: quarterly revenue landed at €15.2b and basic ea
An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters.
Regeneron rallied to a two-year high as Dupixent drives strong Q3 earnings. But is there any further upside left in REGN shares? Let’s find out!
Shares of biotech company Regeneron (NASDAQ:REGN) jumped 11.5% in the afternoon session after the company reported a 36% increase in third-quarter 2026 revenue to $5.1 billion, alongside a 70% rise in non-GAAP diluted ea
Eurozone growth just cooled to 0.4% in Q3, yet still beat forecasts, and that mix of resilience and slowdown is quietly reshaping where money could flow next. Some businesses may benefit if investors rethink how far the
Welcome to the SNY (Sanofi ADS) Roar Pit. Current RQD Composite is 59/100 (Roarable Hold — Cautious Neutral) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on SNY, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless Sanofi ADS expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on SNY, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $43.13 (52-wk range $39.07 - $52.68), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).